| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 01/08/2003 | CN1389234A Lithiasis treating medicine |
| 01/08/2003 | CN1098256C Substd. benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors |
| 01/07/2003 | US6504057 Fluorophenyl-substituted alkenylcarboxylic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament containing them |
| 01/07/2003 | US6504034 Cell antiproliferative agents; anticancer agents |
| 01/07/2003 | US6504007 GDNF receptor |
| 01/07/2003 | US6503935 Imidazoles and related compounds as α1A agonists |
| 01/07/2003 | US6503930 Pyrazole derivatives as p38 kinase inhibitors |
| 01/05/2003 | CA2390181A1 Sulfonyl aryl triazoles as anti-inflammatory/analgesic agents |
| 01/03/2003 | WO2003000896A2 POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-5 GENE |
| 01/03/2003 | WO2003000864A2 Nucleic acid-associated proteins |
| 01/03/2003 | WO2003000699A1 Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene derivatives as medicaments for the treatment of pain |
| 01/03/2003 | WO2003000694A1 6-phenyldihydropyrrolopyrimidinedione derivatives |
| 01/03/2003 | WO2003000691A1 Carboline derivatives as pdev inhibitors |
| 01/03/2003 | WO2003000688A1 Azaindoles |
| 01/03/2003 | WO2003000684A1 Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (pai-1) |
| 01/03/2003 | WO2003000678A1 Cyanoanthranilamide derivatives and the use thereof as medicaments |
| 01/03/2003 | WO2003000677A1 Spiropiperidine compounds as ligands for orl-1 receptor |
| 01/03/2003 | WO2003000671A1 Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 01/03/2003 | WO2003000668A1 Oxa(thia)zolidine compounds, process for preparation thereof and anti-inflammatory agents |
| 01/03/2003 | WO2003000666A1 5-ht receptor ligands and uses thereof |
| 01/03/2003 | WO2003000663A1 5-ht receptor ligands and uses thereof |
| 01/03/2003 | WO2003000285A1 Tissue-specific transporter inhibitor |
| 01/03/2003 | WO2003000276A1 Anti-aromatase composition consisting of a mixture from plants extracts |
| 01/03/2003 | WO2003000273A1 Modulating serum amyloid a interaction with tanis and agents useful for same |
| 01/03/2003 | WO2003000257A1 TGF-ß SUPERFAMILY PRODUCTION/SECRETION PROMOTER |
| 01/03/2003 | WO2003000195A2 Method and material for treating immune diseases |
| 01/03/2003 | WO2003000185A2 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/03/2003 | WO2003000181A2 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | WO2003000180A2 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | WO2002087605A3 Modified fvii in treatment of ards |
| 01/03/2003 | WO2002087596A3 Use of azithromycin for the manufacture of a medicament for treatment of non-infective inflammatory diseases |
| 01/03/2003 | WO2002083667A3 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 01/03/2003 | WO2002072584A3 Tetrahydro-pyrazino (1,2-a) indoles for the treatment of central nervous disorders |
| 01/03/2003 | WO2002048163A3 PROCESSES FOR THE PREPARATION OF αGAL(1→4)βGAL(1→4)GLC-OR TRISACCHARIDES |
| 01/03/2003 | WO2002046170A8 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto |
| 01/03/2003 | WO2002034741A3 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE |
| 01/03/2003 | WO2002010387A3 G-protein coupled receptors |
| 01/03/2003 | WO2002002603A3 Protein modification and maintenance molecules |
| 01/03/2003 | WO2002000727A3 Gp286 nucleic acids and polypeptides |
| 01/03/2003 | CA2455292A1 5-ht receptor ligands and uses thereof |
| 01/03/2003 | CA2451885A1 Method and material for treating immune diseases |
| 01/03/2003 | CA2451250A1 Modulating serum amyloid a interaction with tanis and agents useful for same |
| 01/03/2003 | CA2450969A1 Nucleic acid-associated proteins |
| 01/03/2003 | CA2450579A1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | CA2450550A1 Spiropiperidine compounds as ligands for orl-1 receptor |
| 01/03/2003 | CA2450491A1 5-ht receptor ligands and uses thereof |
| 01/03/2003 | CA2450478A1 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 01/03/2003 | CA2450475A1 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/03/2003 | CA2449844A1 Naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) |
| 01/02/2003 | US20030004351 Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threonine kinase inhibitors |
| 01/02/2003 | US20030004350 Pyrrolo(2,3-b)pyridine derivatives; anticancer and antiproliferative agents |
| 01/02/2003 | US20030004212 Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists |
| 01/02/2003 | US20030004194 Method for treating fibrotic diseases or other indications VI |
| 01/02/2003 | US20030004174 Antiinflammatory agents, anticancer agents, antihistamines, central nervous system disorders |
| 01/02/2003 | US20030004166 Novel triazine compounds useful as sorbitol dehydrogenase inhibitors |
| 01/02/2003 | US20030004165 Polyazanaphthalene compounds and pharmaceutical use thereof |
| 01/02/2003 | US20030004164 Anticancer agents; autoimmune diseases |
| 01/02/2003 | US20030004161 Anticancer agents; autoimmune diseases |
| 01/02/2003 | US20030004157 Neurokinin antagosnist receptor |
| 01/02/2003 | US20030004151 Cyclic derivatives as modulators of chemokine receptor activity |
| 01/02/2003 | US20030004144 Anticancer agents; skin disorders |
| 01/02/2003 | US20030004139 Antidiabetic agents |
| 01/02/2003 | US20030004137 Muscle relaxants, controlling immunology, strokes, antidiabetic agents |
| 01/02/2003 | US20030004132 Binding to galectins; therapy for autoimmune disease |
| 01/02/2003 | US20030004110 Therapeutic compositions and methods for enhancing angiogenesis |
| 01/02/2003 | US20030003559 Nucleotide sequences coding polypeptide for use in the treatment of diabetes, kidney, and liver disorders |
| 01/02/2003 | US20030003094 Compound which disrupts microtubule function and polymeric carrier, with proviso that polymeric carrier is not a capsule |
| 01/02/2003 | US20030003082 Use of poly-Glu,Tyr and T cells treated therewith for neuroprotective therapy |
| 01/02/2003 | US20030003079 Recombinant pox virus for immunization against tumor-associated antigens |
| 01/02/2003 | US20030003077 A genetic engineered adenoviral vector contains an adenoviral genome from which the open reading frames E1 and/or E3 were deleted and a therapeutic gene or a DNA sequence that encodes for therapeutic proteins useful in fibrosis treatment |
| 01/02/2003 | EP1270558A1 "Compound for the treatment of atherosclerotic-thrombotic pathological conditions" |
| 01/02/2003 | EP1270044A2 Wound healing biomarkers |
| 01/02/2003 | EP1270004A1 Diuretics containing gamma-tocotrienol |
| 01/02/2003 | EP1268861A2 Diagnosis of diseases associated with dna transcription |
| 01/02/2003 | EP1268857A2 Diagnosis of diseases associated with gene regulation |
| 01/02/2003 | EP1268793A2 Fibroblast growth factor receptor-like molecules and uses thereof |
| 01/02/2003 | EP1268761A2 Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising the same, and methods of use thereof |
| 01/02/2003 | EP1268554A2 Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using a specific chemokine receptor analysis and the chemokine receptor-ligand interaction |
| 01/02/2003 | EP1268549A2 Method of identifying inhibitors of tie-2 |
| 01/02/2003 | EP1268503A1 O-glucosylated benzamide sglt2 inhibitors and method |
| 01/02/2003 | EP1268502A1 O-aryl glucoside sglt2 inhibitors and method |
| 01/02/2003 | EP1268498A1 Cardioprotective phosphonates and malonates |
| 01/02/2003 | EP1268487A1 Tricyclic protein kinase inhibitors |
| 01/02/2003 | EP1268480A1 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors |
| 01/02/2003 | EP1268468A1 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylat and polymorphs |
| 01/02/2003 | EP1268465A1 Triarylimidazole derivatives as cytokine inhibitors |
| 01/02/2003 | EP1268455A2 Piperazine derivatives |
| 01/02/2003 | EP1268453A1 Estrogen agonist/antagonist metabolites |
| 01/02/2003 | EP1268448A1 Bicyclic amine derivatives as inhibitors of class 1 receptor tyrosine kinases |
| 01/02/2003 | EP1268445A1 4-amino-5-cyano-2-anilino-pyrimidine derivatives and their use as inhibitors of cell-cycle kinases |
| 01/02/2003 | EP1268444A1 2,4-di(hetero-)arylamino(-oxy)-5-substituted pyrmidines as antineoplastic agents |
| 01/02/2003 | EP1268437A1 Inhibitors of protein kinases |
| 01/02/2003 | EP1268431A1 3-cyanoquinolines,3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
| 01/02/2003 | EP1268419A1 Pyrrolidine derivatives useful as bax inhibitors |
| 01/02/2003 | EP1268389A2 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators |
| 01/02/2003 | EP1267915A2 Methods of treating diseases with activated protein c |
| 01/02/2003 | EP1267902A1 Cosmetic use of hop and ornithine |
| 01/02/2003 | EP1267888A1 Use of low dosage bisphosphonates to inhibit cardiac and arterial calcification |
| 01/02/2003 | EP1267886A2 Vitamin d compounds used to stabilize kidney transplants |
| 01/02/2003 | EP1267841A1 Controlled release pharmaceutical composition containing midodrine and/or desglymidodrine |